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Abstract
The proliferative B-13 pancreatic cell line is unique in its ability to generate functional hepa-
tocyte-like (B-13/H) cells in response to exposure to glucocorticoid. In these studies, quanti-
tatively comparable hepatic levels of liver-specific and liver-enriched transcription factor
and hepatocyte defining mRNA transcripts were expressed after 10–14 days continuous
treatment with glucocorticoid. This conversion in phenotype was associated with increased
Gr-αmRNA expression and translation of a functional N-terminally truncated variant protein
that localized to the nucleus in B-13/H cells. A short (6 hours) pulse exposure to glucocorti-
coid was also sufficient to transiently activate the Gr and irreversibly drive near identical
conversion to B-13/H cells. Examination of epigenetic-related mechanisms demonstrated
that B-13 DNA was rapidly methylated and de-methylated over the initial 2 days in response
to both continuous or pulse exposure with glucocorticoid. DNA methylation and glucocorti-
coid-dependent conversion to an hepatic B-13/H phenotype was blocked by the methylation
inhibitor, 5-azacytidine. Conversion to an hepatic B-13/H phenotype was also blocked by
histone deacetylase inhibitors. Previous experiments have identified N-terminal Sgk1 vari-
ant proteins as pivotal to the mechanism(s) associated with pancreatic–hepatic differentia-
tion. Both continuous and pulse exposure to DEX was sufficient to result in a near-similar
robust transcriptional increase in Sgk1c mRNA expression from undetectable levels in B-13
cells. Notably, expression of Sgk1c mRNA remained constitutive 14 days later; including
after pulse exposure to glucocorticoid and this induction was inhibited by 5-azacytidine or
by histone deacetylase inhibitors. These data therefore suggest that exposing B-13 cells to
glucocorticoid results in a Gr-dependent pulse in DNA methylation and likely other epige-
netic changes such as histone modifications that leads to constitutive expression of Sgk1c
and irreversible reprogramming of B-13 cells into B-13/H cells. Understanding and applica-
tion of these mechanism(s) may enhance the functionality of stem cell-derived hepatocytes
generated in vitro.
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Introduction
The B-13 cell line is a progenitor cell line with an unusual capacity to generate comparatively
near-functional hepatocyte-like (B-13/H) cells after treatment with glucocorticoid hormone
alone [1–3]. This can be achieved on simple plastic culture sub-strata and appears to be related
to a pathophysiological response of both rodent and human pancreas exocrine and/or progeni-
tor cells to elevated glucocorticoid in vivo [4–6]. The capacity to generate near functional hepa-
tocyte-like cells from B-13 cells is exemplified by the expression of functional drug
metabolising enzymes in the B-13/H phenotype. B-13/H cells have been shown to express simi-
lar rat hepatocyte levels of total (carbon monoxide/reduced spectrally detectable) cytochromes
P450 [7] and associated testosterone hydroxylation [2], para-nitrophenol hydroxylase activity
[8], alkylresorufin dealkylase activities [9], Luciferin-IPA [9], paracetamol, diclofenac, bupro-
pion and midazolam metabolism [7]. There is also limited expression of phase 2 conjugation
activities such as glucuronidation and sulphation [10]. Given this apparent unique response,
the B-13 cell line may have significant practical applicability in Toxicology as a platform to
screen drug and chemical metabolism and toxicity [9,3]. However, the cell line is also a valuable
model for understanding progenitor cell regulation in the pancreas and liver, since progenitors
isolated from primary tissues are low in abundance, and on isolation, undergo a rapid irrevers-
ible transition to a rapidly proliferating mesenchymal phenotype that precludes their effective
study [3].
Stem cells are a potential source of hepatocytes that could be used to study a variety of clini-
cal and basic science questions and applications. However, at present, generating stem cell-
derived hepatocytes remains challenging in terms of the resources required and level of func-
tionality. At present, foetal-levels of expression of many genes preclude their use in many
cases, most notably in toxicity studies [11]. This laboratory and others have therefore investi-
gated a number of signaling pathways involved in B-13/H generation in part, to understand
how stem cell-derived hepatic phenotype might be amplified to normal in vivo levels. In this
respect, roles for the glucocorticoid receptor (Gr) [1], serine/threonine protein kinase 1 (Sgk1)
[12], Wnt signalling [8] and induction of the liver-enriched transcription factors C/EBPα and
C/EBPβ in the trans-differentiation have been identified [1,7].
In this paper, we demonstrate for the first time that glucocorticoid exposure results in the
up-regulation of Gr mRNA expression and expression of a transcriptionally active N-termi-
nally truncated Gr protein that shows increased nuclear localisation in B-13/H cells. We then
demonstrate that Gr activation for just a short 6 hour period is sufficient to initiate trans-differ-
entiation, that this is dependent on irreversible epigenetic changes at both the DNA and his-
tone protein level and likely leads to the constitutive expression of a variant Sgk1c mRNA
transcript.
Materials and Methods
Constructs
A sequence containing a concatamer of 4 glucocorticoid response elements (GREs) upstream
of a eukaryotic minimal promoter was designed based on an alignment of the sequences of the
GREs from the tyrosine amimontransferase gene (TAT); the tryptophan oxygenase gene (TO);
the human metallothionein gene, hMT; the murine sarcoma virus (MSV), the human growth
hormone gene (hGH) and the mouse mammary tumour virus (MMTV)–see S1 Fig. Oligonu-
cleotide sequences were synthesized (plus and minus strand followed by annealing as previ-
ously outlined [13] and inserted into the pGL4.28 luciferase reporter plasmid construct
(Promega, Southampton, UK) at the XhoI and BglII restriction sites using standard methods.
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Recombinants (GRE4–pGL4.28) were cloned and sequence checked prior to archiving the
clone.
Animal tissues and cells
Male Sprague-Dawley rats (230-250g body weight) were purchased from Charles River (Kent,
UK) and housed in accordance with Home Office guidelines. Rat hepatocytes were isolated by
collagenase perfusion as outlined [9] under a UK Home Office license with Newcastle Univer-
sity Local Ethics Committee approval that includes specific approval for this study. Rat liver
and pancreas tissue was isolated during perfusion procedures to reduce the number of animals
used and total RNA isolated from snap frozen tissue or tissue homogenates prepared as out-
lined [2].
B-13 Cell Culture
B-13 cell line was sub-cloned from the rat adenocarcinoma AR42J cell line (archived at the
American Type Culture Collection and available from a variety of commercial suppliers) by
the Kojima lab [14]. For an extensive review of the origin of both the AR42J and B-13 cell lines,
see [3]. B-13 cells were routinely cultured in 6 well plates in low glucose Dulbecco’s minimum
essential medium (DMEM) supplemented with 10% (v/v) foetal calf serum (FCS), 80u/ml peni-
cillin and 80μg/ml streptomycin (1.5 mls/well). Cells were incubated at 37°C in a humidified
incubator gassed with 5% CO2 in air. Dexamethasone (DEX) was purchased from the Sigma
Chem Co. (Poole, UK) and was added to medium from 1000-fold concentrated ethanol vehicle
solvated stocks, control cells were treated with 0.1% (v/v) ethanol alone as control. Medium
was routinely replaced every 2–3 days, unless otherwise stated. Cells treated continuously for
10–14 days with DEX are referred to as B-13/H cells (B-13 cells with an hepatocyte phenotype).
For all DEX time course experiments, cells were seeded 24 hours prior to DEX administration.
For cells treated with 10 nM DEX for 6 hours only, after six hours exposure to DEX, cells were
washed three times with 3mls/well of PBS (137mMNaCl, 2.7mM KCl, 10mM phosphate pH
7.4) and media replaced with standard DMEM culture media (i.e. supplemented with 10% (v/
v) FCS, 80u/ml penicillin and 80μg/ml streptomycin). Typically 85% - 95% of B-13 cells trans-
differentiated into B-13/H cells with continuous DEX treatment as judged by phenotypic
observation [4]. B-13/H cells do not proliferate and therefore to reduce interference from a
minor proliferating population of B-13 cells in analyses, B-13 cells were exposed to DEX once
they had achieved a near confluence (reducing the expansion of B-13 cells). Maximal trans-dif-
ferentiation occurred after 10–14 days treatment with further treatment not increasing the
number of trans-differentiated cells/well.
RT-PCR and qRT-PCR
Total RNA was purified using Trizol (Invitrogen, Paisley, UK). RT-PCR was carried out as pre-
viously outlined and using primer sequences given in [9]. Quantitative RT-PCR employed the
use of an Applied Biosystems7500 Real-Time PCR machine, using SYBR1 Green Jumpstart™
master mix (Sigma-Aldrich, UK), with 2μM forward and reverse primer. Additional primer
sequences and primers for RT-PCR are given in Table 1.
Western blotting
Western blotting was performed essentially as previously outlined [4]. Antibodies for Cyp2e,
Cps1, Cebpα/β, Oct4, Sox, c-myc, Klf4 and Gr (BuGR2) were purchased from Abcam (Cam-
bridge, UK), β-actin from Sigma (Poole, Dorset) and albumin fromMP Biomedicals
Epigenetics and B-13/H Cells
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Table 1. Primers used for RT-PCR and qRT-PCR.
Oligo ID Primer sequence (5’-3’) Comments
RT-PCR
rSgk1c US AAGTAACCCCAGCCTTCACC Will amplify rat Sgk1c - also referred to as variant 2 (NM_001193569.1) cDNA sequence of
143bp–see Wallace et al., 2011 supplementary data section.
DS GCATGCATAGGAGTTGTTGG
rGr-α US GCGACAGAAGCAGTTGAGTCATC Will hybridise to rat Gr cDNA (NM_012576.2) sequence of 103bp. Also transcript variants X1
(XM_008772065.1) and X2 (XM_008772066.1).
DS CCATGCCTCCACGTAACTGTTAG
rGr-β US GCGCTTGAGGCTAAGATAGCT Will hybridise to rat Gr-β cDNA sequence of 108bp as reported by DuBois et al., (2013).
DS CCCATGTTTCTGCCTCTTTCTTTG
rDnmt1 US TACGCAAGGTTTGAGTCCCC Will hybridise to rat Dnmt1 cDNA (NM_053354.3) sequence of 191bp.
DS CCCAGTCGGTAGACAACACC
rDnmt3a US GCTATTTACAGAGCTTCGGGC Will hybridise to rat Dnmt3a cDNA transcript variant 2 (NM_001003957.1) sequence of 125bp.
DS TGGCTTTCCTCCACAGCATT
rDnmt3b US CCAAGGCGTATTCGTCGC Will hybridise to rat Dnmt3b cDNA (NM_001003959.1) sequence of 161bp.
DS TACGTTTACTTGGGCCGCTT
rTet1 US TATATGGCTGTGCTGCCCAA Will hybridise to rat Tet1 variant X1cDNA (XM_006256398.2) sequence of 212bp.
DS CGATGGGCCATTGCTTGATG
rTet2 US TGTTGTCAGGGTGAGAATCCAG Will hybridise to rat Tet2 cDNA variant X1 (XM_006233347.2), X2 (XM_008761534.1) and X3
(XM_227694.7) sequences of 225bp.
DS CCTGTAGGCATCAGGTGCAA
rTet3 US CCCTTGCCTGAAGCATCTCA Will hybridise to rat Tet3 cDNA (XM_008763095.1 and several variants) sequence of 311bp.
DS GCCGAGGTACCATTCCCAAA
rTgd US GCTTCAACCGCACAAGATCC Will hybridise to rat Tgd cDNA (NM_053729.1) sequence of 196bp.
DS CTGCAGGTCGAACGTGTACT
rMecp2 US GCGACGTTCCATCATTCGTG Will hybridise to rat Mecp2 cDNA (NM_022673.2) sequence of 77bp.
DS TAAGCTTTCGCGTCCAACCT
rAicda US AAATGGCCCCACGTTCCTAC Will hybridise to rat Aicda cDNA (NM_001100779.1) sequence of 428bp.
DS TGGTCTTGTGCCTTGCCTTT
Gapdh US TGACATCAAGAAGGTGGTGAAG Will amplify rat (NM 017008), human (NM 002046) or mouse (NM 008084) glyceraldehyde 3
phosphate dehydrogenase cDNA sequence of 243bp.
DS TCTTACTCCTTGGAGGCCATGT
qRT-PCR
rAmylase US TGGCCGCGTGACAGAATTCAAGTA Will hybridise to rat pancreatic Amy2a3 cDNA (NM_031502.1) sequence of 175bp at 59°C to
produce a single amplimer.
DS TCCAGCACCATGTCCTCGCT
rCebp-α US ATAAAGCCAAACAGCGCAAC Will hybridise to rat Cebp-α cDNA (NM_012524.2) sequence of 67bp at 54°C to produce a
single amplimer.
DS CGGTCATTGTCACTGGTCAA
rCebp-β US CTTCAGCCCCTACCTGGAG Will hybridise to rat Cebp-β cDNA (NM_024125.4) sequence of 88bp at 55°C to produce a
single amplimer.
DS GAGGTCGGAAAGGAAGTCGT
rCyp2e1 US CTGACTGTCTCCTCATAGAGATGG Will hybridise to rat xCyp2e1 cDNA (NM_031543.1) sequence of 78bp at 55°C to produce a
single amplimer.
DS TCACAGAAACATTTTCCATTGTGT
rAlbumin US TGGTCGCAGCTGTCCGTCAGA Will hybridise to rat albumin cDNA (NM_134326.2) sequence of 192bp at 61°C to produce a
single amplimer.
DS CGCATTCCAACAGGTCGCCG
rCpsI US TGTGAAGGTCTTGGGAACATCGGT Will hybridise to rat CpsI cDNA (NM_017072.1) sequence of 173bp at 59°C to produce a
single amplimer.
(Continued)
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(Cambridge, UK). Anti-amylase antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Detection was achieved using appropriate horseradish-peroxidase-conju-
gated anti-IgG secondary antibodies and chemiluminescence (ECL, GE Healthcare, Amer-
sham, UK).
Immunostaining
B-13 cells were grown on chamber slides and permeabilised with ice-cooled methanol for 10
minutes before washing in PBS and fixing in 2% w/v formaldehyde, 0.2% gluteradehyde in
PBS. Non-specific binding of antibodies was blocked through incubation with 20% (v/v) bovine
foetal calf serum (FCS) in PBS for 20 minutes at room temperature. Samples were then incu-
bated with the relevant primary antibody diluted in 0.05% (v/v) FCS and left to incubate over-
night at 4°C. Samples were washed twice in PBS before applying appropriate FITC conjugated
secondary antibodies for 1 hour at RT. Cells were mounted in Vectashield with DAPI (Vector
Labs) prior to examination.
Transfection
B-13 cells were seeded into 6 well plates 24 hours prior to transfection and cultured in standard
culture media. Cells were transfected with 2 μg GRE4–pGL4.28 reporter plasmid (or pGL4.28,
Table 1. (Continued)
Oligo ID Primer sequence (5’-3’) Comments
DS ACCGAATCATCACAGGGTAGCCAA
rHNF1-α US CTCAGCACCAGTCCCACAG Will hybridise to rat Hnf1-α cDNA (NM_012669.1) sequence of 64bp at 56°C to produce a
single amplimer.
DS CGTTGGAGTCAGAACTCTGGT
rHnf1-β US TCCTCTCACCTGACAGTAAAATGAT Will hybridise to rat Hnf1-β cDNA (NM_013103.1) sequence of 73bp at 55°C to produce a
single amplimer.
DS ATATTCGTCAAGGTGCTGACC
rHnf4-α US AGCAATGGACAGATGTGTGAGT Will hybridise to rat Hnf4-α cDNAs from transcript variant 2 (NM_001270931.10 and Hnf4α
transcript variant 1 (NM_022180.2) sequence of 93bp at 55°C to produce a single amplimer.
DS AGATCCAGAGCCACTTGGTG
rFoxa1 US CATGAGAGCAACGACTGGAA Will hybridise to rat Foxa1 cDNA (NM_012742.1) sequence of 83bp at 54°C to produce a
single amplimer.
DS CCGGAGTTCATGTTGCTGA
rFoxa2 US TCCCTGGGACTTAACTGTAACG Will hybridise to rat Foxa2 cDNA (NM_012743.1) sequence of 74bp at 55°C to produce a
single amplimer.
DS ACGGCTCCCAGCATACTTT
rFoxa3 US ACTACCGGGAGAACCAGCA Will hybridise to rat Foxa3 cDNA (NM_017077.2) sequence of 61bp at 57°C to produce a
single amplimer.
DS TCATTGAAGGACAGCGAGTG
rGr-α US GTGCTGACATGTGGAAGCTG Will hybridise to rat Gr-α cDNA (NM_012576.2) sequence of 86bp at 54°C to produce a single
amplimer. Since this primer pair amplifies a region of the Gr transcript encoded from exons 1
and 2, this primer pair will also amplify any Gr-β transcripts.
DS CAATCGTTTCTTCCAGCACA
rMecp2 US TGGTAGCTGGGATGTTAGG Will hybridise to rat Mecp2 cDNA (NM_022673.2) sequence of 219bp at 55°C to produce a
single amplimer.
DS AACTTCAGGGGTTTCTCTTTGAG
18s
rRNA
US CCCGAAGCGTTTACTTTGAA Will amplify 136bp of rat 18s rRNA.
DS CCCTCTTAATCATGGCCTCA
doi:10.1371/journal.pone.0150959.t001
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see S1 Fig) and 0.2 μg Renilla Luciferase (RL-TK) per well using Lipofectamine1 transfection
reagent, according to the manufacturer’s instructions, and cultured for 48 hours prior to treat-
ment. Luciferase activities were analysed using a Dual Glo1 luciferase assay system (Promega,
Southampton, UK) and a luminometer. Luciferase activities were normalised to renilla activi-
ties, to control for any variations in transfection efficiencies between wells.
DNAmethylation
Total global methylation was determined using a Sigma Imprint1Methylated DNA quantifi-
cation kit, essentially according to the manufacturer’s instructions. Typically, 100ng of DNA
from each treatment was analysed in compared to standard methylated DNA provide in the
kit. Relative global methylation levels were calculated as percentage compared to the fully
methylated control.
Statistical analysis
The student's T test (two tailed) was used to test for statistical significances.
Results
B-13 differentiation to B-13/H cells involves a co-ordinated alteration in
gene expression leading to hepatic levels of hepatocyte-specific/
hepatocyte-enriched gene expression
The B-13 cell line was derived from the exocrine rat pancreas (for review, see [3]) and Fig 1A
demonstrates that treatment with 10nM dexamethasone (DEX) glucocorticoid resulted in an
initial increase in the expression of pancreatic amylase mRNA as previously reported [1]. Fig
1B shows that Cebp-α expression was induced early (typically around day 2), followed by
Cebp-β. After day 5 there was a more robust induction of the Cebp mRNA transcripts and
induction in the expression of liver-specific (or enriched) mRNAs (CpsI, Cyp2e1 and albu-
min). This latter change occurred around the time that amylase expression was markedly sup-
pressed (between 4–6 days after DEX treatment–Fig 1A). The notable feature of the B-13
response was the quantitative change in expression of liver-specific and liver-enriched tran-
scripts suggestive of a robust coordinated alteration to an hepatic phenotype, despite the sim-
plicity of the culture conditions. To test this conclusion, the quantitative expression of liver-
specific/enriched mRNAs was examined for the first time by direct quantitative comparison to
intact rat liver and rat pancreas tissue. Fig 1C and 1D demonstrate comparable mRNA levels of
expression of Cebp, Hnf and Foxa transcription factors in liver and B-13/H cells, and compara-
ble levels of expression of functional hepatic genes (Fig 1E).
Glucocorticoid exposure therefore stimulated B-13 cell trans-differentiation to B-13/H cells
which, based on quantitative levels of expression of liver-specific and liver-enriched transcrip-
tion factor and hepatocyte defining mRNA transcripts, demonstrated a similar phenotype to
hepatocytes.
Glucocorticoid exposure results in an induction of Gr mRNA expression
and expression of a transcriptionally active N-terminally truncated Gr
protein with increased nuclear localisation in B-13/H cells
Previous work has shown that B-13 cells express the Gr mRNA and that the closely related
mineralocorticoid receptor is lowly expressed and not involved in the differentiating effects of
glucocorticoids in B-13 cells [12]. Fig 2A suggests that B-13 cells expressed primarily the Gr-α
isoform transcript (with only low levels of the truncated variant Gr-βmRNA detectable), the
Epigenetics and B-13/H Cells
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orthologue of which has been shown to function in a dominant-negative fashion in man [15].
Fig 2A also suggests that the Gr-αmRNA transcript increases in abundance after conversion to
B-13/H cells and this was confirmed by quantitative RT-PCR analysis (Fig 2B). However,
Western blotting of cell extracts and comparison with several tissues—including liver—sug-
gests that the Gr protein was expressed at relatively high levels in both B-13 and B-13/H cells.
It has recently become clear that the human Gr-α gene produces a variety of N-terminally trun-
cated Gr-α proteins with unique transcriptional targets and that their presence in cells is not a
result of artefact proteolysis, but generated through altered translational start sites from a single
mRNA species [16]. A similar phenomenon is reported to occur in rat and mouse [16]. Since
the Gr gene is highly conserved, the rat and human Gr-α amino acid sequence was aligned and
used to predict truncated rat Gr-α proteins and calculate their theoretical molecular weights
(S2 Fig). This analysis predicted D isoforms in rat of around 50 kDa (in contrast to the full
length Gr-α-A protein of 87.4 kDa). Fig 2C suggests that the full length Gr-α-A and Gr-α-D
forms were present in B-13 cells and only the Gr-α-D form in B-13/H. The Gr-α-D form in
human cells was reported to be localised predominantly to the nucleus and to be transcription-
ally active [16]. Immunocytochemical staining in B-13 and B-13/H cells indicated that there
was increased localization of Gr-α in the nucleus of B-13/H cells whereas there was no marked
difference in B-13 cells (Fig 2D). Transfecting both cell phenotypes with a Gr-responsive
reporter gene construct (pGRE4-pGL4.28) indicated that the Gr in B-13 cells was transcrip-
tionally-active in a dose-dependent fashion at concentrations above approx. 1-10nM DEX.
Interestingly, without the addition of DEX, the Gr in both cell phenotypes was transcription-
ally-inactive (Fig 2E).
The Gr-α was therefore expressed at relatively high levels in B-13 and B-13/H cells. Activa-
tion with ligand resulted in increased Gr-αmRNA expression and increased translation of an
N-terminally truncated variant transcriptionally functional protein that predominantly local-
ized to the nucleus in B-13/H cells.
A short 6 hour exposure to glucocorticoid is sufficient to initiate an
irreversible conversion of B-13 cells to B-13/H cells
We have previously noted that the process of B-13 cell trans-differentiation into B-13/H cells
appeared to be irreversible, in that removal of glucocorticoid from differentiating cells neither
halts the process nor leads to a reversion back to the B-13 phenotype (unpublished observa-
tions). We therefore hypothesized that glucocorticoid exposure in B-13 cells initiates an epige-
netic change(s) that accounts for the inability of B-13/H cells to revert back to B-13 cells (and
which may also be critical for their near quantitative functional trans-differentiation into hepa-
tocytes). To test this hypothesis, B-13 cells were exposed to a pulse of glucocorticoid for just 6
hours prior to extensive washing and culture in normal medium routinely used to expand the
B-13 cells (i.e. without supplementation with DEX, and which does not lead to trans-differenti-
ation into B-13/H cells).
Fig 3 demonstrates that a short pulse exposure to glucocorticoid resulted in an activation of
the transcriptional function of the Gr within the time frame of the pulse exposure but also
Fig 1. Quantitative RT-PCR determination of transcripts in B-13, B-13/H cells and comparison to rat liver and pancreas levels. Time course for the
expression of amylase mRNA (A) or Cebp-α (-■-), Cebp- β (-●-), albumin (-▲-) and Cyp2e1 (-♦) mRNAs (B) in B-13 cells after treatment with 10nM DEX. Data
are mean and standard deviation of three independent experiments. B-13 cells treated with 0.1% (v/v) ethanol (i.e. vehicle control) had minimal effect on all
transcripts and are not shown for clarity. After 3–4 days, B-13 cells unexposed to DEX required sub-culturing since they continued to proliferate to avoid cell
death. Therefore, they were not appropriate controls for B-13 cells treated with DEX after this time since DEX treatment resulted in a cessation of proliferation
and sub-culture was not required.C—E, Expression levels of the indicated 18S rRNA-normalised transcript, relative to the levels present in B-13 cells, data
are the mean and standard deviation of at least 3 separate cell samples/rat tissue samples.
doi:10.1371/journal.pone.0150959.g001
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confirmed that the washing procedure fully reversed Gr transcriptional activity by 24 hours
(Fig 3A). Despite only a pulse of Gr activation, Fig 3B demonstrates that there was a similar
induction of liver-specific/enriched transcription factors (Fig 3B and 3C) and expression of
liver markers (Fig 3D) to levels close to those seen in B-13/H cells (i.e. after constant DEX
exposure) after 10–14 days of culture, as determined by qRT-PCR. Furthermore, B-13 cells
exposed to 6 hours of glucocorticoid formed morphologically similar cells to B-13/H cells at
10–14 days (Fig 3E), and expression of liver-specific proteins were, as seen with B-13/H cells,
similar to the levels seen in intact liver (Fig 3F).
Immunocytochemistry confirmed that there was a widespread loss of amylase expression
and an increase in Cepb-α and albumin expression after both DEX treatment regimens (S3
Fig). The comparable quantitative expression of mRNAs in B-13 cells treated with DEX for 6
hours only was not therefore due to a small population of cells expressing relatively high levels
of these transcripts and offsetting a widespread lack of responsiveness in the majority of cells
(remaining as proliferative B-13 cells).
In contrast to effectively blocking on-going activation of the Gr through washing out DEX,
addition of the Gr antagonist RU486 after a period of Gr activation by DEX markedly inhibited
the trans-differentiation to B-13/H cells (S4 Fig). This outcome suggests that the activation of
the Gr and transcriptional effect become functionally fixed in B-13 cells when DEX is washed
out, but that this effect may be blocked if the Gr transcriptional function is antagonized by sub-
sequent exposure to a Gr antagonist.
These data demonstrate that a relatively short (6 hours) pulse exposure to glucocorticoid
was sufficient to transiently activate the Gr and irreversibly drive B-13 cell trans-differentiation
to B-13/H cells to a quantitatively similar hepatic level 10–14 days later, in the absence of Gr
antagonist. This response suggests that the effects triggered around the time period of pulse
exposure (less than 24 hours) is sufficient to direct B-13 cells toward an hepatic B-13/H
phenotype.
Inhibition of glucocorticoid-initiated epigenetic changes in B-13 cells
blocks trans-differentiation into B-13/H cells
To test the hypothesis that an epigenetic change(s) is critical in the trans-differentiation of B-
13 cells to B-13/H cells, the methylation of DNA was examined at various time points after the
addition of DEX. Fig 4A demonstrates that genomic DNA was methylated within hours of
exposure to DEX, peaking around 12 hours, followed by de-methylation and apparent stabili-
zation throughout subsequent morphological changes to B-13/H cells. Pulse exposure to DEX
resulted in a similar peak in DNA methylation (Fig 4A). A screen for the expression of a variety
of DNA methylation transcripts indicated that a restricted number were expressed in B-13/H
cells compared to rat liver, and that expression of all those examined were relatively low in B-
13 cells (Fig 4B). To test for a potential functional effect of DNA methylation in B-13 cells
exposed to DEX, the levels of the Mecp2 mRNA were examined by qRT-PCR, since the protein
product of this gene binds to methylated DNA as part of the methylation-associated
Fig 2. Expression and transcriptional function of Gr in B-13 and B-13/H cells. A, RT-PCR analysis for the expression of rat Gr mRNA transcripts (Gr-α
and Gr-β) in the indicated cell and tissue samples. The Gr-β variant uses an alternate acceptor splice site at the 3' terminal exon resulting in a frame-shift and
a shorter isoform with a distinct C-terminus compared to the α isoform. Data are typical of at least 4 separate B-13 and B-13/H cell cultures, after 30 cycles.B,
Expression levels of the Gr-αmRNA transcripts relative to 18S rRNA transcript levels, and then normalised to B-13 cell. Data are the mean and standard
deviation of at least 3 separate cell samples/rat tissue samples.C, Western blot for Gr protein, total cell protein/lane, B-13 and B-13/H 10μg/lane; rat tissue
samples, 40μg/lane, typical of at least 4 separate investigations.D, Immunocytochemical staining for Gr (green) in B-13 and B-13/H cells with DNA stained
using DAPI (blue), typical of 3 separate investigations. Arrow with circled dotted line indicates position of a cell nucleus, bar = 50μm. E, Gr transcriptional
function as determined through transfection of GRE4-pGL4.28 and measurement of luciferase and renilla activities. Data are the mean and standard
deviation of 3 separate transfections in the same experiment, typical of 3 separate experiments.
doi:10.1371/journal.pone.0150959.g002
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mechanism of gene repression or induction [17]. Fig 4C demonstrates that there was an induc-
tion of Mecp2 mRNA transcripts after the pulse in DNAmethylation that was maximal
(approx. 12-fold) 48 hours after exposure to DEX, suggesting that the pulse in DNA methyla-
tion may be functional and have a significant functional role in B-13 cell differentiation. To test
this hypothesis, B-13 cells were pre-treated with the DNA methylation inhibitor 5-azacytidine
(5AZA) [18]. The effect of high concentrations of DMSO (2% [v/v])–which promotes the
hydroxylation of methylated DNA [19]–was also examined. Fig 4D demonstrates that the Gr
antagonist RU486, which is known to block glucocorticoid-dependent B-13 trans-differentia-
tion to B-13/H cells [1,12], inhibited DEX-dependent DNAmethylation, confirming that the
pulse in DNAmethylation is Gr-dependent. Fig 4D also demonstrates that 5AZA significantly
inhibited DEX-induced DNA methylation, whereas DMSO had minimal effect. Both 5AZA
and DMSO (S5 Fig)–in addition to inhibitors of histone modifications trichostatin A and
sodium butyrate [20,21] markedly inhibited DEX-induced B-13 trans-differentiation to B-13/
H cells based on almost complete inhibition of hepatic Cyp2e1 and albumin protein expression
(Fig 4E) and inhibition of morphological changes (Fig 4F).
Previous experiments with B-13 cells have identified N-terminal Sgk1 variant proteins as
pivotal to the mechanism(s) associated with pancreatic–hepatic differentiation. Notably,
ectopic expression of 2 human variants–C (also termed variant 3) and F–in B-13 cells was suffi-
cient to promote B-13 trans-differentiation to B-13/H cells in the absence of glucocorticoid.
Expression of other human SGK1 isoforms, including the wild type A (or variant 1) had no
effect on B-13 cell trans-differentiation to B-13/H cells [12]. Since a 6 hour pulse exposure to
DEX was sufficient to initiate B-13 cell trans-differentiation to B-13/H cells, a comparison of
the effects of constant DEX and a 6 hour pulse of DEX treatment on Sgk1c mRNA expression
was examined. Because the Sgk1c mRNA transcript contains only a short 5’ nucleotide
sequence specific to the transcript, a primer pair suitable for use in qRT-PCR could not be
designed that specifically amplified a region of this transcript. Accordingly, a semi-quantitative
RT-PCR assay was developed and transcript levels quantified by image analysis of the predicted
PCR product band in ethidium bromide stained gels. Fig 5A and 5B demonstrates that a 6
hour exposure to DEX was sufficient to result in a near-similar robust increase in Sgk1c mRNA
expression from undetectable levels in B-13 cells, when compared to cells exposed throughout
with DEX. Fig 5C further indicates that the mechanism of induction of Sgk1c mRNA was
wholly transcriptional since the RNA polymerase inhibitor actinomycin d [22] blocked Sgk1c
mRNA expression in response to hours DEX. Note, that a variant orthologous to the F variant
has not been identified in rat. Addition of DNAmethylation inhibitor 5-azacytidine or the
inhibitors of histone modifications—trichostatin A and sodium butyrate–blocked the induc-
tion of Sgk1c mRNA transcript expression by DEX (Fig 5D), suggesting that the constitutive
expression of this transcript after DEX exposure is dependent on DEX-dependent epigenetic
alterations in B-13 cells.
Fig 3. Limiting B-13 cell exposure to glucocorticoid for 6 hours results in a near quantitatively identical trans-differentiation to the B-13/H
phenotype. A, Gr transcriptional activity in B-13 cells after the indicated period of time of treatment with DEX and/or RU486. “6 hours DEX treatment” refers
to cells pulse treated with DEX for 6 hours prior to washing as outlined in methods section. Cells were transfected as outlined in methods section with
GRE4-pGL4.28 and RL-TK prior to measurement of luciferase and renilla activities. Data are the mean and standard deviation of 3 separate transfections in
the same experiment, typical of 3 separate experiments. *Significantly different (two tailed) normalised luciferase reporter gene activity versus control vehicle
treated cells; $significantly different (two tailed) normalised luciferase reporter gene activity versus DEX only treated cells, P > 0.05.B–D, Expression levels
of the indicated 18S rRNA normalised transcript relative to the levels present in B-13 cells (open bars) 14 days after continuous DEX treatment (grey bars) or
limited 6 hours DEX treatment (hashed bars), data are the mean and standard deviation of at least 3 separate cell samples. E, Photomicrographs of B-13
cells 14 days after continuous DEX treatment or limited 6 hours DEX treatment. F, Western blot for the indicated protein in B-13 cells 14 days after continuous
DEX treatment or limited 6 hours DEX treatment.
doi:10.1371/journal.pone.0150959.g003
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These data therefore show that exposing B-13 cells to DEX results in a Gr-dependent pulse
in DNA methylation and likely other epigenetic changes such as histone modifications and to
the constitutive expression of Sgk1c, even after only transient DEX exposure.
Discussion
The B-13 cell is a unique cell line in that its differentiation into hepatocyte-like B-13/H cells
results in a relatively quantitatively comparative cell to its in vivo hepatocyte equivalent. To
date, the only factors known to trigger this response are glucocorticoids via the Gr nuclear
receptor. The mechanisms involved in the formation of B-13/H cells involve an induction of
selected Sgk1 isoforms which cross talk into the Wnt signalling pathway leading to a transient
repression in Wnt activity and induction of Cebp-β [5, 12, 1]. Similar observations have been
observed in vivo under pathological conditions, suggesting that the B-13 cell over-responds to
physiologically relevant glucocorticoid in an analogous manner to that observed in normal
pancreatic acinar cells in response to injury/stress [23, 24] (for a recent review see also [3]) and
to high pathological levels of systemic glucocorticoid [5].
This paper confirms for the first time, that glucocorticoid exposure in B-13 cells resulted in
a B-13/H phenotype that is remarkably similar to an hepatocyte phenotype as judged on the
quantitative levels of expression of liver-specific, liver-enriched transcription factor and hepa-
tocyte defining mRNAs and that a pulse exposure to glucocorticoid was sufficient to irrevers-
ibly convert B-13 cells to B-13/H cells. Exposure to glucocorticoid led to a pulse in DNA
methylation and conversion to B-13/H cells that were blocked by the DNA methylation inhibi-
tor 5AZA, suggesting that DNA methylation is essential for B-13 cell trans-differentiation to B-
13/H cells and constitutes a component of the mechanism that prevents reversion from B-13/
H to B-13 cell. High concentrations of DMSO also blocked B-13 cell trans-differentiation to B-
13/H, suggesting that hydroxylation of methylated DNA inhibits the formation of an hepatic
phenotype. Histone deacetylase inhibitors also blocked B-13 cell trans-differentiation to B-13/
H, indicating that histone modification is also a component of this mechanism.
Previous work has demonstrated that a major induced transcript in B-13 cells exposed to
glucocorticoid is that encoding Sgk1 [4]. More recent evidence strongly implicates variant Sgk1
transcripts as pivotal in the process of pancreatic–hepatic differentiation. In transgenic mice
with high levels of circulating endogenous glucocorticoid, pancreata expressing a variety of
liver markers also expressed detectable levels of the murine orthologue of Sgk1c, whereas wild
type mice expressed neither liver markers nor Sgk1c mRNA [25, 12]. In pancreata from
patients undergoing pancreatectomies, the C and F isoform mRNAs of SGK1 where not detect-
able. In contrast, the pancreas from a patient exposed long term to systemic glucocorticoid
treatment and whose pancreas expressed high (liver levels) of a range of hepatic proteins,
expressed readily detectable levels of the C and F mRNA isoforms [6]. In human acinar cells in
culture that expressed hepatic markers in response to high concentrations of DEX, both C and
Fig 4. Glucocorticoid treatment results in a pulse of DNAmethylation that is dependent on the Gr and is essential for B-13 cell trans-differentiation
to B-13/H cells. A, genomic DNAmethylation in B-13 cells treated as indicated [DEX (6 hrs), B-13 cells treated with a pulse 6 hour treatment]. B, RT-PCR
analysis for the expression of the indicated transcript in the indicated cell and tissue samples. C, qRT-PCR for Mecp2 mRNA in the indicated time point,
expressed relative to the levels present in B-13 cells. Data are the mean and standard deviation of 3 determinations from the same experiment, typical of 3
separate experiments. D, genomic DNAmethylation in B-13 cells at the peak of methylation after DEX treatment (12 hours) with treatments as indicated.
Data are the mean and standard deviation of 3 determinations from the same experiment, typical of 3 separate experiments. *Significantly different (two
tailed) DNAmethylation versus control vehicle treated cells; $significantly different (two tailed) DNAmethylation versus DEX only treated cells, P > 0.05. E,
Western blot for the indicated proteins in B-13 cells treated for 14 days as indicated, results typical of at least 3 separate determinations. F, Photomicrographs
of B-13 cells 7 days after continuous DEX treatment with or without the indicated epigenetic inhibitors or vehicle control (cells were pre-treated with these
inhibitors 2 hours before first exposure to DEX). Medium was changed as outlined in methods section with DEX and epigenetic inhibitor treatments renewed
at each media change (results typical of at least 8 separate experiments.
doi:10.1371/journal.pone.0150959.g004
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F isoform mRNAs were also induced, whereas in acinar cells which did not respond to DEX,
there was no induction of these isoforms [6]. Since Sgk1c mRNA expression remains constitu-
tively expressed in B-13 cells after transcriptional induction by transient exposure to DEX, it is
likely that epigenetic alterations are a major mechanism responsible for this apparent irrevers-
ible response. Future work is currently being directed to identifying the precise epigenetic
changes controlling Sgk1c expression in B-13 cells since it may be applied to stem cells and
potentiate differentiated phenotypes in vitro.
The advent of the REACH regulations in the EU means that a large number of chemicals
will have to be assessed for their safety, a requirement that precludes the widespread use of ani-
mals in toxicity testing on both financial and ethical Grounds. A major goal in Toxicology is
therefore to find computational and in vitromethods to screen chemicals for potential toxici-
ties. Given the target organ toxicity paradigm, near equivalent functional comparability of in
vitro cells to in vivo is important if in vitro assessments are to be predictive of human suscepti-
bility when dealing with the general population and exposures. This is particularly relevant for
the liver, where high levels of chemical metabolising enzymes are a major determinant in hepa-
totoxicity [26]. In view of the shortages, costs and variability in obtaining human hepatocytes,
stem cell-derived hepatocytes are a realistic alternative for toxicity screening. However, stem
and progenitor cells currently fail to generate fully differentiated functional mature cells in
vitro despite their intrinsic capacity to do so in vivo [11]. An understanding of the mechanism
(s) involved in the trans-differentiation to B-13/H cells may inform on the approaches required
to generate a human equivalent.
Supporting Information
S1 Fig. Derivation of a reporter construct conferring glucocorticoid receptor (Gr) respon-
siveness. A, alignment of several Gr response elements and derivation of a consensus glucocor-
ticoid response element (GRE) sequence. Alignment of the sequences of the GREs from the
tyrosine amimontransferase gene (TAT); the tryptophan oxygenase gene (TO); the human
metallothionein gene, hMT; the murine sarcoma virus (MSV), the human growth hormone
gene (hGH) and the mouse mammary tumour virus (MMTV) as reported by Jantzen et al.,
1987. B, sequence of 4 GREs (GRE4-) cloned into the pGL4.28 luciferase reporter construct as
outlined in methods section. C, GRE4- sequence conferred responsiveness to DEX. B-13 cells
were seeded into 6 well plates 24 hours prior to transfection and cultured in standard culture
media. Cells were transfected with 2 µg/well pGL4.28 or GRE4–pGL4.28 reporter plasmid and
0.2 µg/well renilla luciferase (RL-TK) using Lipofectamine1 transfection reagent, as outlined
by the manufacturer, left for 48 hours prior to treatment with either control vehicle (0.1% [v/v]
ethanol) or DEX as indicated. Luciferase activities were analysed using a Dual Glo1 luciferase
assay system (Promega, Southampton, UK) and a luminometer. Luciferase activities were
Fig 5. DEX-induced Sgk1cmRNA expression in B-13 cells is transcriptionally induced from constitutively low levels in B-13 cells and induction is
imprinted by pulse DEX exposure. A, Gel electrophoresis of RT-PCR products designed to amplify a region specific to the rat Sgk1c mRNA transcript (143
bp as indicated). The identity of the high molecular weight band is unknown and was not always evident between different experiments. B-13 cells were
treated in triplicate with 10nMDEX continuously for 14 days or for a 6 hour pulse as indicated and RNA isolated and Sgk1C and Gapdh mRNA transcript
levels examined by RT-PCR at the indicated times. Each separate experiment is shown. B-13 cells treated with 0.1% (v/v) ethanol (i.e. vehicle control) had
minimal effect on all transcripts were as for time 0 (not included). After 3–4 days, B-13 cells require sub-culturing since they continue to proliferate. Therefore,
they are not appropriate controls for B-13 cells treated with DEX after this time since DEX treatment results in a cessation of proliferation and sub-culture is
not required and also leads to significant cell loss.B, semi-quantitative image analysis of Sgk1c band intensity, mean and standard deviation of the three
separate experiments shown in A. C, Effect of actinomycin d (0.3μg/ml) on the induction of Sgk1c mRNA transcript in response to 6 hours exposure to 10nM
DEX. After 6 hours exposure to the indicated treatments, cells were washed and cultured in standard media with DEX or actinomycin d. Each separate
experiment is shown.D, Effect of the indicated epigenetic inhibitor on the induction of Sgk1c mRNA transcript in response to continuous exposure to 10nM
DEX in B-13 cells, time after treatment initiation as indicated on left of panels. Results typical of 3 separate experiments.
doi:10.1371/journal.pone.0150959.g005
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normalised to renilla activities, to control for any variations in transfection efficiencies between
wells. Data are the mean and standard deviation of 3 separate experiments, typical of 3 separate
experiments. Significantly different (two tailed) normalised luciferase reporter gene activity
versus control vehicle treated cells, P> 0.05.
(TIF)
S2 Fig. Alignment of amino acid sequences of rat and human GRα proteins. CLUSTAL O
(1.2.0) multiple sequence alignment was used to align the sequences. Molecular weights were
of rat GRα isoforms was calculated using software available at http://web.expasy.org/compute_
pi/.
(PDF)
S3 Fig. Immunocytochemical staining of B-13 and B-13/H cells. Immunocytochemical
staining for the indicated antigen in B-13 cells 14 days after either continuous DEX treatment
or limited 6 hours DEX treatment after subsequent culture to 14 days, No 1° Ab CONTROL
MERGE, DAPI and FITC fluorescence merge after identical incubations with the exception of
the primary antibody. Results typical of at least 3 separate experiments.
(TIF)
S4 Fig. Effect of subsequent exposure to Gr antagonism on pulsed DEX-induced B-13 cell
trans-differentiation to B-13/H cells.Western blot for the indicated proteins in B-13 cells
treated with DEX or 0.1% ethanol vehicle control (-) for 2 days (

or continuously with DEX for
14 days to generate B-13/H cells) followed by washing and treatment with RU486 or 0.1% etha-
nol vehicle control (-) for the subsequent 5 days. Cells were analyzed at the time points indi-
cated. Results typical of at least 3 separate determinations.
(TIF)
S5 Fig. Effect of DMSO on DEX-induced B-13 cell trans-differentiation to B-13/H cells.
Western blot for the indicated proteins in B-13 cells treated for 14 days as indicated, results
typical of at least 3 separate determinations.
(TIF)
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